Non-Hodgkin lymphoma (NHL) is a group of related blood cancers, with risk and outcomes varying by subtype and stage. In the U.S. and worldwide, it remains common, and diffuse large B-cell lymphoma (DLBCL) is the most frequent adult subtype. On this page, you’ll see which people are most affected, the immune-linked factors that increase risk (including immunosuppression, HIV, EBV, and autoimmune disease), and what common symptoms can look like. You’ll also get a clear view of survival and treatment approaches tied to these patterns.
Key Takeaways
- In the United States, approximately 80,620 new cases of non-Hodgkin lymphoma (NHL) are expected to be diagnosed in 2024, representing about 4% of all new cancer cases.
- The age-adjusted incidence rate for NHL in the US from 2017-2021 was 18.6 cases per 100,000 people per year based on SEER data.
- Globally, NHL accounted for 544,000 new cases in 2020, making it the 11th most common cancer worldwide according to GLOBOCAN.
- Immunosuppression from organ transplant increases NHL risk 30-50 fold.
- HIV infection raises NHL risk by 100-fold, particularly for aggressive subtypes.
- Epstein-Barr virus (EBV) is associated with 70-80% of endemic Burkitt lymphoma cases.
- Overall 5-year survival for NHL is 74% in the US from 2014-2020 data.
- DLBCL 5-year relative survival is 64% overall, 91% for localized stage.
- Follicular lymphoma 5-year survival exceeds 90% for low-grade cases.
- B symptoms (fever, night sweats, weight loss) occur in 20-30% of NHL patients at diagnosis.
- Lymphadenopathy is the most common presenting symptom in 70-80% of NHL cases.
- Bone marrow involvement is found in 30-40% of NHL patients via biopsy.
- R-CHOP regimen is first-line for 70-80% of DLBCL cases.
- Overall response rate to R-CHOP in DLBCL is 90-95%.
- Autologous stem cell transplant (ASCT) used in 20-30% of relapsed DLBCL.
In the US about 80,620 new non Hodgkin lymphoma cases are expected in 2024, with strong survival overall.
Related reading
01 · Category
Incidence And Prevalence30 stats
01
In the United States, approximately 80,620 new cases of non-Hodgkin lymphoma (NHL) are expected to be diagnosed in 2024, representing about 4% of all new cancer cases.
02
The age-adjusted incidence rate for NHL in the US from 2017-2021 was 18.6 cases per 100,000 people per year based on SEER data.
03
Globally, NHL accounted for 544,000 new cases in 2020, making it the 11th most common cancer worldwide according to GLOBOCAN.
04
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL, comprising 30-40% of all cases in adults.
05
In Europe, the incidence rate of NHL has been stable at around 10-15 per 100,000 since 2000, per Eurostat data.
06
Among US males, the lifetime risk of developing NHL is 2.24%, higher than females at 1.60% from 2018-2021 data.
07
NHL incidence peaks in individuals aged 75-84 years, with a rate of 88.7 per 100,000 in that age group in the US.
08
In 2022, China reported 102,000 new NHL cases, the highest globally due to population size.
09
Follicular lymphoma accounts for 20-25% of NHL cases in Western countries.
10
The prevalence of NHL in the US as of 2021 was estimated at 837,356 survivors.
11
Incidence of NHL among non-Hispanic whites in the US is 19.8 per 100,000, higher than Blacks at 13.4.
12
From 2000-2020, global NHL incidence increased by 25% due to aging populations.
13
Mantle cell lymphoma represents 5-10% of NHL cases, more common in men over 60.
14
In Australia, NHL incidence is 24.5 per 100,000 for males and 15.8 for females.
15
Pediatric NHL comprises 3-4% of childhood cancers, with Burkitt lymphoma being prominent.
16
HIV-associated NHL incidence has declined 10-fold since the introduction of ART.
17
In Japan, NHL incidence is lower at 10.5 per 100,000, with higher T-cell lymphoma proportion.
18
Marginal zone lymphoma accounts for 7-8% of NHL, often in older adults.
19
US female NHL incidence rate is 13.4 per 100,000 from 2017-2021.
20
Global 5-year prevalence of NHL in 2020 was 1.4 million cases.
21
Incidence of primary CNS lymphoma, a rare NHL subtype, is 0.4 per 100,000.
22
In the UK, 13,000 new NHL cases annually, with DLBCL at 40%.
23
NHL rates have risen 3-4% annually in developing countries since 1990.
24
Anaplastic large cell lymphoma (ALCL) is 2% of NHL, higher in young males.
25
US Asian/Pacific Islander NHL incidence is 10.2 per 100,000.
26
In 2020, India had 50,000 NHL cases, driven by infectious associations.
27
Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia is 1-2% of NHL.
28
Incidence in US Hispanics is 14.5 per 100,000 from recent SEER data.
29
Global mortality from NHL in 2020 was 259,000 deaths.
30
Peripheral T-cell lymphoma not otherwise specified is 25-30% of T-cell NHL.
Interpretation
Incidence And Prevalence Interpretation
For the incidence and prevalence angle, non-Hodgkin lymphoma is showing a consistently high burden in the United States with about 80,620 new cases expected in 2024 and an age-adjusted incidence rate of 18.6 per 100,000 people per year from 2017 to 2021, while globally it reached 544,000 new cases in 2020 and remains one of the world’s most common cancers.
02 · Category
Risk Factors And Etiology26 stats
01
Immunosuppression from organ transplant increases NHL risk 30-50 fold.
02
HIV infection raises NHL risk by 100-fold, particularly for aggressive subtypes.
03
Epstein-Barr virus (EBV) is associated with 70-80% of endemic Burkitt lymphoma cases.
04
Autoimmune diseases like rheumatoid arthritis increase NHL risk by 2-4 times.
05
Helicobacter pylori infection is linked to 90% of gastric MALT lymphomas.
06
Pesticide exposure raises NHL risk by 40-50% in agricultural workers per meta-analyses.
07
Obesity (BMI >30) is associated with a 1.2-1.5 fold increased NHL risk.
08
Hepatitis C virus (HCV) infection increases marginal zone lymphoma risk 10-fold.
09
Family history of NHL doubles the risk in first-degree relatives.
10
Smoking has a modest association, increasing DLBCL risk by 20-30%.
11
Sjögren's syndrome elevates NHL risk 40-fold, especially MALT type.
12
Celiac disease increases enteropathy-associated T-cell lymphoma risk 30-fold.
13
Hair dyes use before 1980 increased NHL risk by 1.5 times in women.
14
HTLV-1 infection causes 100% of adult T-cell leukemia/lymphoma cases.
15
Methotrexate use in autoimmune disease raises NHL risk 2-3 fold.
16
Farming occupation correlates with 1.4-fold NHL risk due to solvents.
17
Human herpesvirus 8 (HHV8) is implicated in 90% of primary effusion lymphomas.
18
Alcohol consumption may reduce NHL risk by 20-30% in moderate drinkers.
19
Benzene exposure is linked to a 1.5-2 fold increase in NHL incidence.
20
Post-transplant lymphoproliferative disorder (PTLD) occurs in 2-10% of solid organ recipients.
21
Male gender has a 1.3-1.5 relative risk for most NHL subtypes.
22
Age over 60 years increases NHL risk exponentially, peaking at 75+.
23
Breast implants are associated with rare anaplastic large cell lymphoma (BIA-ALCL).
24
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) links to rare NHL.
25
Ionizing radiation exposure from CT scans slightly elevates risk (SIR 1.2).
26
Common variable immunodeficiency (CVID) raises NHL risk 30-fold.
Interpretation
Risk Factors And Etiology Interpretation
Across major risk factors for Non Hodgkins Lymphoma, immune disruption stands out as the key theme since immunosuppression from organ transplants increases risk 30 to 50 fold and HIV raises it about 100 fold, alongside clear infection links like EBV in 70 to 80% of endemic Burkitt lymphoma and Helicobacter pylori driving 90% of gastric MALT cases.
03 · Category
Survival And Prognosis25 stats
01
Overall 5-year survival for NHL is 74% in the US from 2014-2020 data.
02
DLBCL 5-year relative survival is 64% overall, 91% for localized stage.
03
Follicular lymphoma 5-year survival exceeds 90% for low-grade cases.
04
Mantle cell lymphoma median OS is 5-7 years with intensive therapy.
05
Stage I NHL 5-year survival 82.5%, Stage IV 63.2% per SEER.
06
High IPI score (4-5) in DLBCL has 5-year OS of 33%.
07
CAR-T therapy 3-year OS 47% in refractory large B-cell lymphoma.
08
Pediatric NHL 5-year survival 90% with modern protocols.
09
Transformed follicular lymphoma median survival 2-3 years post-transformation.
10
Burkitt lymphoma 5-year survival 60% in adults, 90% in children.
11
Relapsed DLBCL post-ASCT median OS 12 months.
12
Low FLIPI follicular lymphoma 10-year survival 70-80%.
13
Primary CNS lymphoma 5-year survival 30-40% with MTX-based therapy.
14
T-cell NHL 5-year survival 30-40% overall.
15
Age <60 with DLBCL has 5-year OS 80% vs. 50% over 60.
16
Marginal zone lymphoma indolent type 10-year OS 65%.
17
HIV-NHL survival improved to 50% at 3 years with ART integration.
18
PTLD 5-year survival 60% for localized, 30% disseminated.
19
ALCL ALK-positive 5-year survival 80-90%, ALK-negative 40%.
20
Median survival for double-hit lymphoma 18-24 months.
21
R-CHOP era improved DLBCL OS by 10-15% vs. CHOP alone.
22
Elderly (>80) NHL 5-year survival 40%.
23
Curative radiation alone Stage I 90-95% 10-year DFS.
24
Peripheral T-cell lymphoma 5-year OS 32%.
25
Post-relapse survival in indolent NHL 5 years median.
Interpretation
Survival And Prognosis Interpretation
Across common NHL types and stages, survival varies widely, with overall 5 year survival at 74% in the US but dropping sharply from 82.5% for Stage I to 63.2% for Stage IV and even to 33% 5 year OS in high IPI DLBCL, showing that prognosis is strongly stage and risk dependent.
04 · Category
Symptoms And Diagnosis25 stats
01
B symptoms (fever, night sweats, weight loss) occur in 20-30% of NHL patients at diagnosis.
02
Lymphadenopathy is the most common presenting symptom in 70-80% of NHL cases.
03
Bone marrow involvement is found in 30-40% of NHL patients via biopsy.
04
Elevated LDH levels are present in 40-50% of aggressive NHL at diagnosis.
05
PET-CT scan has 90-95% sensitivity for staging NHL.
06
Ann Arbor staging: Stage I in 10-15%, Stage IV in 40-50% of cases.
07
Fatigue affects 60-70% of patients with advanced NHL.
08
Extranodal involvement in 30-40% of NHL, GI tract most common (17%).
09
Flow cytometry detects aberrant immunophenotypes in 95% of B-cell NHL.
10
Cytogenetic analysis reveals t(14;18) in 85-90% of follicular lymphoma.
11
Pruritus occurs in 10-20% of NHL patients, especially cutaneous types.
12
Bone pain from involvement in 5-10% of cases.
13
IPI score: Low risk in 35%, high risk in 16% of DLBCL patients.
14
MRI is used for CNS involvement detection in 20% of high-grade cases.
15
Splenomegaly present in 30-50% of advanced NHL.
16
Biopsy diagnostic yield is 95% for excisional lymph node biopsies.
17
Hypercalcemia occurs in 15% of adult T-cell lymphoma cases.
18
Next-generation sequencing identifies mutations in 80% of DLBCL.
19
Mediastinal mass causes SVC syndrome in 5% of NHL presentations.
20
Thrombocytopenia at diagnosis in 20-30% of leukemic phase NHL.
21
Endoscopy detects gastric involvement in 5-10% of NHL.
22
FLIPI score categorizes follicular lymphoma risk in 90% accuracy.
23
Skin lesions in primary cutaneous follicle center lymphoma in 4% of NHL.
24
Lumbar puncture positive for CNS disease in 5-10% high-risk cases.
25
Anemia (Hb<10g/dL) in 30% of symptomatic NHL patients.
Interpretation
Symptoms And Diagnosis Interpretation
At diagnosis, most NHL patients first show up with lymphadenopathy in 70 to 80 percent of cases, while B symptoms appear in only 20 to 30 percent, and staging is often advanced with Ann Arbor Stage IV present in 40 to 50 percent of patients despite PET CT’s 90 to 95 percent sensitivity.
05 · Category
Treatment Options25 stats
01
R-CHOP regimen is first-line for 70-80% of DLBCL cases.
02
Overall response rate to R-CHOP in DLBCL is 90-95%.
03
Autologous stem cell transplant (ASCT) used in 20-30% of relapsed DLBCL.
04
Rituximab maintenance post-remission improves PFS by 10% in follicular lymphoma.
05
CAR-T therapy (axicabtagene ciloleucel) achieves 82% ORR in refractory large B-cell lymphoma.
06
Radiation therapy is curative in 90% of stage I-II marginal zone lymphoma.
07
BTK inhibitors like ibrutinib yield 60-70% response in mantle cell lymphoma.
08
Polatuzumab vedotin added to R-CHP improves survival by 23% in DLBCL.
09
Watchful waiting applied to 20-30% of low-grade asymptomatic follicular lymphoma.
10
Lenalidomide + rituximab achieves 90% ORR in follicular relapsed cases.
11
Allogeneic transplant 5-year OS 40-50% in high-risk relapsed NHL.
12
H. pylori eradication cures 70-80% early gastric MALT lymphoma.
13
Brentuximab vedotin ORR 86% in relapsed ALCL.
14
Tazemetostat (EZH2 inhibitor) 70% ORR in follicular lymphoma with mutations.
15
R-ICE salvage regimen response rate 70% pre-ASCT in DLBCL.
16
Proton therapy reduces cardiac toxicity by 50% in mediastinal NHL.
17
Venetoclax + obinutuzumab PFS superior by 50% vs. chemotherapy in follicular.
18
Chemotherapy alone curative in 60-70% pediatric Burkitt lymphoma.
19
Bispecific antibodies like glofitamab 52% CR in relapsed B-cell NHL.
20
Involved site radiation (ISRT) used in 40% early-stage favorable NHL.
21
PI3K inhibitors like duvelisib ORR 43% in relapsed follicular lymphoma.
22
Hyper-CVAD achieves 90% CR in Burkitt lymphoma adults.
23
Mosunetuzumab bispecific 80% ORR in follicular relapsed.
24
ASCT 5-year PFS 50% in chemosensitive relapsed aggressive NHL.
25
Copanlisib (PI3K inhibitor) 59% ORR in indolent NHL.
Interpretation
Treatment Options Interpretation
For Treatment Options in lymphoma care, the numbers show that modern strategies are often highly effective, with R-CHOP used in 70 to 80 percent of DLBCL cases and delivering a 90 to 95 percent response rate while specialized approaches like CAR-T reach an 82 percent ORR in refractory disease.
report visual · Comparison
Non-Hodgkin Lymphoma: Incidence vs Prevalence
US incidence and prevalence highlight the scale of NHL burden—new diagnoses and the number of people living with the disease.
The prevalence of NHL in the US as of 2021 was estimated at 837,356 survivors.837,356
Globally, NHL accounted for 544,000 new cases in 2020, making it the 11th most common cancer worldwide according to GLOB
544,000
Global 5-year prevalence of NHL in 2020 was 1.4 million cases.
5
In the United States, approximately 80,620 new cases of non-Hodgkin lymphoma (NHL) are expected to be diagnosed in 2024,
4%
report visual · Key figures
Key NHL Risk Factors by Strength of Association
Several infections and immune dysfunctions are strongly associated with higher NHL risk, while some exposures show more modest effects.
30
Immunosuppression from organ transplant increases NHL risk 30-50 fold.
100
HIV infection raises NHL risk by 100-fold, particularly for aggressive subtypes.
-80%
Epstein-Barr virus (EBV) is associated with 70-80% of endemic Burkitt lymphoma cases.
2
Autoimmune diseases like rheumatoid arthritis increase NHL risk by 2-4 times.
90%
Helicobacter pylori infection is linked to 90% of gastric MALT lymphomas.
-50%
Pesticide exposure raises NHL risk by 40-50% in agricultural workers per meta-analyses.
report visual · Breakdown
Survival depends on lymphoma type and extent
Higher survival is seen in localized/indolent settings and in some subtypes, while advanced stage and high-risk features substantially lower survival.
60%
Burkitt lymphoma 5-year survival 60% in adults, 90% in children.
40%
Elderly (>80) NHL 5-year survival 40%.
report visual · Breakdown
Non-Hodgkin Lymphoma: Common Symptoms vs Diagnostic Detection
Key symptom patterns appear in a substantial share of patients, while multiple diagnostic tests show high sensitivity or strong detection rates.
95%
Flow cytometry detects aberrant immunophenotypes in 95% of B-cell NHL.
5%
Mediastinal mass causes SVC syndrome in 5% of NHL presentations.
report visual · Key figures
Treatment response rates and first-line use in major NHL subtypes
Illustrate how common DLBCL first-line therapy compares with response rates from advanced options (e.g., CAR-T), and contrast with response likelihood in other NHL subtypes.
-80%
R-CHOP regimen is first-line for 70-80% of DLBCL cases.
-95%
Overall response rate to R-CHOP in DLBCL is 90-95%.
-30%
Autologous stem cell transplant (ASCT) used in 20-30% of relapsed DLBCL.
10%
Rituximab maintenance post-remission improves PFS by 10% in follicular lymphoma.
82%
CAR-T therapy (axicabtagene ciloleucel) achieves 82% ORR in refractory large B-cell lymphoma.
90%
Radiation therapy is curative in 90% of stage I-II marginal zone lymphoma.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Margot Villeneuve. (2026, February 13). Non Hodgkins Lymphoma Statistics. Gitnux. https://gitnux.org/non-hodgkins-lymphoma-statistics
MLA
Margot Villeneuve. "Non Hodgkins Lymphoma Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/non-hodgkins-lymphoma-statistics.
Chicago
Margot Villeneuve. 2026. "Non Hodgkins Lymphoma Statistics." Gitnux. https://gitnux.org/non-hodgkins-lymphoma-statistics.
Sources & references
14 datasets cited across this report · attribution is report-level